Dr. Moshe Neuman (Motzi) is one of the founding fathers of clinical research and clinical trial design and management in Israel. As the CEO of the Elmar Company, I have worked closely with Dr. Neuman and became well aware of his inexhaustible knowledge, in regulatory affairs of pharmaceuticals and medical devices, as well as his vast experience in clinical trials design and management and I have been using them for over 20 years, which has contributed greatly to the success of the projects we lead.
I know Dr Moshe Neuman for many years and worked with him on several projects. Dr. Neuman is highly knowledgeable in the fields of drug and device development, as well as with the associated clinical studies and regulatory affairs.
Over the last few years, I’ve had the opportunity to work with Dr. Neuman and B.R.D CRO Team, on a major phase II clinical study for Foamix Pharmaceuticals, Ltd. We found B.R.D CRO to be professional, familiar with the highest degree of GCP research compliance and to be both; cost and time-effective, all of which contributed to the overall success of our product development.
I have known Dr. Moshe Tzvi Neuman (Motzi) for many years and worked with him on several projects. Motzi has the rare combination of being highly knowledgeable, efficient, and friendly. He has a wide area of expertise in the critically important fields of drug, biologics and device development, as well as with the design and conduct of preclinical and clinical studies, auditing and quality assurance issues and regulatory affairs.
I have had the pleasure to work with Motzi and the B.R.D team on both preclinical and clinical projects and at each time I received services of the highest quality. In addition to being updated with the most recent regulations (in Israel, Europe and the USA) the team was professional and dedicated and contributed enormously to the success of these projects.
Dear Motzi,
Many thanks! Great job. Thank you for your care, dedication, and attention to details. And, of course, congratulations to you too on the impressive clinical study results and the clinical study report.
I hope we will continue as soon as possible for a follow-up clinical study.
Kind regards,
Asaf